Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Anavex Life Sciences Corp AVXL

Healthcare Biotechnology

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of... see more

Add To Watchlist

Recent & Breaking News (NDAQ:AVXL)

Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

GlobeNewswire June 20, 2023

ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome

GlobeNewswire June 15, 2023

Anavex Life Sciences Reports Publication in Medical Journal Signifying Continued Commitment for Improvement of the Rett Syndrome Caregiver Outcome Measure RSBQ

GlobeNewswire June 12, 2023

Anavex Life Sciences Announces Completion of ANAVEX(®)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

GlobeNewswire June 6, 2023

ANAVEX Announces Issuance of New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine)

GlobeNewswire June 1, 2023

Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results

GlobeNewswire May 9, 2023

Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023

GlobeNewswire May 2, 2023

Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension

GlobeNewswire May 1, 2023

Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

GlobeNewswire April 25, 2023

Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023

GlobeNewswire April 10, 2023

ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson's Disease Dementia

GlobeNewswire March 30, 2023

Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of Biostatistics

GlobeNewswire March 9, 2023

Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

GlobeNewswire February 7, 2023

Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

GlobeNewswire February 2, 2023

Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on Tuesday February 7, 2023

GlobeNewswire January 31, 2023

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer's Trial

GlobeNewswire December 14, 2022

Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 12, 2022

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

GlobeNewswire December 2, 2022

ANAVEX®2-73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer's Disease

GlobeNewswire December 1, 2022

Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

GlobeNewswire November 28, 2022